Literature DB >> 11388076

[Is there progress in chemotherapy for breast cancer?].

C Wenzel1, M Schmidinger, H Huber.   

Abstract

Breast cancer is the most frequent type of cancer in women. The therapeutic approaches to breast cancer have developed rapidly over the past 20 years, due to the increasing knowledge about the biology of breast cancer. Therefore it was possible to increase response rates as well as the duration of response and survival in neoadjuvant, adjuvant, and palliative treatment. This paper gives a review of the current breast cancer trials. Effective new cytotoxic chemotherapy and hormonal therapy agents, as well as the identification of specific molecular abnormalities (HER2/neu) led to the development of targeted therapeutic interventions in the neoadjuvant, adjuvant, and palliative treatment of breast cancer. Increased understanding of the biology of breast cancer led to the development of rational therapeutic interventions, which are currently under active clinical development.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11388076

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN: 0043-5325            Impact factor:   1.704


  1 in total

1.  Prognostic markers in breast cancer: the reliability of HER2/neu status in core needle biopsy of 325 patients with primary breast cancer.

Authors:  Susanne Taucher; Margaretha Rudas; Robert M Mader; Michael Gnant; Peter Dubsky; Sebastian Roka; Thomas Bachleitner; Daniela Kandioler; Günther Steger; Martina Mittlböck; Raimund Jakesz
Journal:  Wien Klin Wochenschr       Date:  2004-01-31       Impact factor: 2.275

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.